Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nazartinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 13/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | CLK2 | P49760 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | ITK | Q08881 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | CDK14 | O94921 | 3/20 | 0.38 |
| ▸ | CCNY | Q8ND76 | 3/20 | 0.38 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CCNH | P51946 | 1/20 | 0.37 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nazartinib SCHEMBL16792310 | 1.00 | EGFR (0.95) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL16792309 | 1.00 | EGFR (0.95) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL18249375 | 1.00 | EGFR (0.95) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL16792305 | 0.99 | EGFR (0.94) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL29786161 | 0.99 | EGFR (0.94) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL16792306 | 0.99 | EGFR (0.94) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL16767238 | 0.97 | EGFR (1.00) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL16767240 | 0.97 | EGFR (1.00) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL16767232 | 0.97 | EGFR (1.00) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL16895924 | 0.97 | EGFR (1.00) | EGFRCYP2D6CYP3A4CYP2C9CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210100812-A1 | Methods for Treating EGFR Mutant Cancers | NOVARTIS AG (CH) | 2021-04-08 | — | — | US | disclosed |
| US-10881664-B2 | Methods for treating EGFR mutant cancers | NOVARTIS AG (CH) | 2021-01-05 | — | — | US | disclosed |
| US-20180153899-A1 | PHARMACEUTICAL COMPOSITIONS | NOVARTIS PHARMA AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20180117059-A1 | METHODS FOR TREATING EGFR MUTANT CANCERS | NOVARTIS PHARMACEUTICALS CORPORATION | 2018-05-03 | — | — | US | disclosed |
| EP-3294299-A1 | METHODS FOR TREATING EGFR MUTANT CANCERS | Novartis AG (CH) | 2018-03-21 | — | — | EP | disclosed |
| EP-3257848-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY | Novartis AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| EP-2773635-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016185333-A1 | METHODS FOR TREATING EGFR MUTANT CANCERS | NOVARTIS AG (CH) | 2016-11-24 | — | — | WO | disclosed |
| US-9440957-B2 | Compounds and compositions for modulating EGFR Activity | NOVARTIS AG (CH) | 2016-09-13 | — | — | US | disclosed |
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881664-B2 | Methods for treating EGFR mutant cancers | EGFR, ERBB2, ERBB3 | EGFR 1/4885CYP2D6 4835/4885CYP3A4 4824/4885 |
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | EGFR, ERBB2, ERBB3 | EGFR 1/4885CYP2D6 4785/4885CYP3A4 4848/4885 |
| US-20180117059-A1 | METHODS FOR TREATING EGFR MUTANT CANCERS | EGFR, ERBB2, ERBB3 | EGFR 1/4885CYP2D6 4835/4885CYP3A4 4824/4885 |
| US-20210100812-A1 | Methods for Treating EGFR Mutant Cancers | EGFR, ERBB2, ERBB3 | EGFR 1/4885CYP2D6 4843/4885CYP3A4 4835/4885 |
| US-20180153899-A1 | PHARMACEUTICAL COMPOSITIONS | NR3C2, PTMS, CYP2C19 | EGFR 2493/4885CYP2D6 40/4885CYP3A4 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.